Evidence map›Paper›PMID 34954204›Full record

ArticleExperimental eye research2022

Intravitreal administration of recombinant human opticin protects against hyperoxia-induced pre-retinal neovascularization.

Izabela P Klaska, Anne White, Pilar Villacampa, Justin Hoke, Laura Abelleira-Hervas, Ryea N Maswood, Robin R Ali, Catey Bunce, Richard D Unwin, Garth J S Cooper and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental eye research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. ASPORIN: A root of the matter in tumors and their host environment.Biochimica et biophysica acta. Reviews on cancer · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 2 countries.

Izabela P KlaskaUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK; KCL Centre for Cell and Gene Therapy, Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.
Anne WhiteDivision of Evolution & Genomic Sciences, School of Biological Sciences, FBMH, University of Manchester, Manchester, UK.
Pilar VillacampaUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK; Josep Carreras Leukaemia Research Institute, Ctra de Can Ruti, Barcelona, Spain.
Justin HokeUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Laura Abelleira-HervasUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Ryea N MaswoodUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Robin R AliUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK; KCL Centre for Cell and Gene Therapy, Tower Wing, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK.
Catey BunceSchool of Population Health and Environmental Sciences, Faculty of Life Sciences and Medicine, King's College London, Addison House, London, SE1 1UL, UK.
Richard D UnwinDivision of Cardiovascular Sciences, School of Medical Sciences, FBMH, University of Manchester, Manchester, UK; Stoller Biomarker Discovery Centre and Division of Cancer Sciences, School of Medical Sciences, FBMH, University of Manchester, Manchester, UK.
Garth J S CooperDivision of Cardiovascular Sciences, School of Medical Sciences, FBMH, University of Manchester, Manchester, UK.
Paul N BishopDivision of Evolution & Genomic Sciences, School of Biological Sciences, FBMH, University of Manchester, Manchester, UK; Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
James W BainbridgeUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK. Electronic address: j.bainbridge@ucl.ac.uk.
University College London · GBUniversity of Manchester · GBGuy's Hospital · GBJosep Carreras Leukaemia Research Institute · ESKing's College London · GBManchester Academic Health Science Centre · GBUniversity College Hospital · GB

Funding

Medical Research Council MR/M025365/1
6 · The paper itself

Abstract

Opticin is an extracellular glycoprotein present in the vitreous. Its antiangiogenic properties offer the potential for therapeutic intervention in conditions such as proliferative diabetic retinopathy and retinopathy of prematurity. Here, we investigated the hypothesis that intravitreal administration of recombinant human opticin can safely protect against the development of pathological angiogenesis and promote its regression. We generated and purified recombinant human opticin and investigated its impact on the development and regression of pathological retinal neovascularization following intravitreal administration in murine oxygen-induced retinopathy. We also investigated its effect on normal retinal vascular development and function, following intravitreal injection in neonatal mice, by histological examination and electroretinography. In oxygen-induced retinopathy, intravitreal administration of human recombinant opticin protected against the development of retinal neovascularization to similar extent as aflibercept, which targets VEGF. Opticin also accelerated regression of established retinal neovascularization, though the effect at 18 h was less than that of aflibercept. Intravitreal administration of human recombinant opticin in neonatal mice caused no detectable perturbation of subsequent retinal vascular development or function. In summary we found that intraocular administration of recombinant human opticin protects against the development of pathological angiogenesis in mice and promotes its regression.

Indexed as

HyperoxiaRetinal NeovascularizationRetinopathy of PrematurityAnimalsDisease Models, AnimalHumansInfant, NewbornIntravitreal InjectionsMiceMice, Inbred C57BLNeovascularization, PathologicOxygenOxygenAngiogenesisNeovascularizationOIROpticinPDRROP

Identifiers

PMID34954204
PMCPMC8935380
OpenAlexW4200274571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.